TY - JOUR AU - Resál, Tamás AU - Bacsur, Péter AU - Keresztes, Csilla AU - Bálint, Anita AU - Bor, Renáta AU - Fábián, Anna AU - Farkas, Bernadett AU - Katsanos, Kostas AU - Michalopoylos, George AU - Ribaldone, Davide Giuseppe AU - Attauabi, Mohamed AU - Zhao, Mirabella AU - Barak, Hadar Amir AU - Yanai, Henit AU - Bezzio, Cristina AU - Rispo, Antonio AU - Castiglione, Fabiana AU - Bar-Gil Shitrit, Ariella AU - Pugliese, Daniela AU - Armuzzi, Alessandro AU - Savarino, Edoardo Vincenzo AU - Kolar, Martin AU - Lukáš, Milan AU - Chashkova, Elena AU - Filip, Rafał AU - Rozieres, Aurore AU - Nancey, Stéphane AU - Krznarić, Željko AU - Schäfer, Eszter AU - Szamosi, A AU - Sarlós, Patrícia AU - Franko, Matej AU - Drobne, David AU - Knyazev, Oleg V AU - Kagramanova, Anna V AU - Limdi, Jimmy AU - Wetwittayakhlang, Panu AU - Lakatos, Péter László AU - Maharshak, Nitsan AU - Bannon, Lian AU - Nyári, Tibor András AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Molnár, Tamás TI - Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis. A Retrospective Worldwide Multicenter Collaborative Study TS - A Retrospective Worldwide Multicenter Collaborative Study JF - INFLAMMATORY BOWEL DISEASES J2 - INFLAMM BOWEL DIS VL - In press PY - 2024 PG - 12 SN - 1078-0998 DO - 10.1093/ibd/izad135 UR - https://m2.mtmt.hu/api/publication/34089134 ID - 34089134 AB - Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC.This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed.A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported.TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found. LA - English DB - MTMT ER - TY - CHAP AU - Urfi, Zsanett Gabriella AU - Nyári, Tibor András AU - Lantos, Tamás ED - Vassányi, István ED - Fogarassyné Vathy, Ágnes TI - A külső halálozások alakulása Magyarországon a 15 év alatti populációban 2000 és 2021 között T2 - Orvosi informatika. A XXXVI. Neumann Kollokvium konferencia-kiadványa PB - Neumann János Számítógép-tudományi Társaság CY - Veszprém SN - 9789633962725 PY - 2023 SP - 127 EP - 132 PG - 6 UR - https://m2.mtmt.hu/api/publication/34449586 ID - 34449586 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Paszt, Attila AU - Simonka, Zsolt AU - Budai, Krisztina AU - Horváth, Zoltán AU - Erdos, Marton AU - Vas, Márton Árpád AU - Ottlakán, Aurél AU - Nyári, Tibor András AU - Szepes, Zoltán AU - Uhercsák, Gabriella AU - Maráz, Anikó AU - Torday, László AU - Tiszlavicz, László AU - Oláh, Judit Magdolna AU - Lázár, György ifj ED - Ottlakán, Aurél ED - Papp, Andras ED - Toth, Dezso ED - Wu, Aiwen TI - Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy T2 - Surgical and Oncological Updates in the Management of Gastric Cancer: the Role of Neoadjuvant Therapy and Minimally Invasive Surgery PB - Frontiers Media S.A. CY - Lausanne SN - 9782832539521 T3 - Frontiers Research Topics, ISSN 1664-8714 PY - 2023 SP - 56 EP - 68 PG - 13 UR - https://m2.mtmt.hu/api/publication/34426094 ID - 34426094 N1 - Másodközlés, eredeti közlés rekordja: 33729458 LA - English DB - MTMT ER - TY - JOUR AU - Bajcsi, Dóra AU - Bitó, László AU - Turkevi-Nagy, Sándor AU - Nyári, Tibor András AU - Kemény, Éva AU - Légrády, Péter AU - Ábrahám, György AU - Iványi, Béla TI - The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy JF - BMC NEPHROLOGY J2 - BMC NEPHROL VL - 24 PY - 2023 IS - 1 PG - 11 SN - 1471-2369 DO - 10.1186/s12882-023-03273-4 UR - https://m2.mtmt.hu/api/publication/34104677 ID - 34104677 AB - The diagnostic performance of PLA2R and IgG subclass staining of kidney biopsies relative to anti-PLA2R seropositivity in the differentiation of primary and secondary membranous nephropathy (pMN, sMN) was examined. Besides PLA2R staining - which has a lower specificity than anti-PLA2R antibody serology - there is insufficient knowledge to decide which IgG1-4 subtype immunohistological patterns (IgG4-dominance, IgG4-dominance/IgG1-IgG4-codominance or IgG4-dominance/IgG4-codominance with any IgG subtype) could be used to distinguish between pMN and sMN.87 consecutive Hungarian patients (84 Caucasians, 3 Romas) with the biopsy diagnosis of MN were classified clinically as pMN (n = 63) or sMN (n = 24). The PLA2R and IgG subclass staining was part of the diagnostic protocol. Anti-PLA2R antibodies were determined by an indirect immunofluorescence test in 74 patients with disease activity.For pMN, the sensitivity of anti-PLA2R seropositivity was 61.1%, and the specificity was 90.0%; and similar values for PLA2R staining were 81.0%, and 66.7%, respectively. In all stages of pMN, IgG4-dominance was the dominant subclass pattern, while the second most frequent was IgG3/IgG4-codominance. The sensitivity and specificity scores were: IgG4-dominance 52.2% and 91.7%, IgG4-dominance/IgG3-IgG4-codominance 76.2% and 87.5%, IgG4-dominance/IgG1-IgG4-codominance 64.2% and 75%, and IgG4-dominance/codominance with any IgG subclass 92.1% and 70.8%, respectively. Anti-PLA2R seropositivity, glomerular PLA2R, and IgG4-dominance/codominance significantly correlated with each other. The IgG4 subclass was rarely encountered in sMN.In our series, IgG4-dominance had the highest specificity in the differentiation of MN, just as high as that for anti-PLA2R seropositivity. The specificity values of PLA2R staining and IgG4-dominance/codominance with any IgG subclass or IgG4-dominance/IgG1-IgG4 codominance were ≤ 75%. Apart from IgG4 dominance, IgG4-dominance/IgG3-IgG4-codominance also had good statistical value in differentiating pMN from sMN. As IgG subclass switching during the progression of pMN was not the feature of our cohort, pMN in Hungarian patients is presumed to be an IgG4-related disorder right from the start. Although anti-PLA2R seropositivity has become the cornerstone for diagnosing pMN, if a kidney biopsy evaluation is conducted, besides the staining of PLA2R antigen, the evaluation of IgG subclasses provides relevant information for a differential diagnosis. Even in cases with IgG4-dominance, however, malignancy should be thoroughly checked. LA - English DB - MTMT ER - TY - CHAP AU - Rachamim, Y AU - Altojay, A AU - Nyári, Tibor András AU - Németh, Gábor László AU - Surányi, Andrea ED - Edward, Prunchunas ED - Sandor, G. Vari ED - Simona, Lauerova ED - Csaba, Vladar TI - Effect of maternal pregestational BMI on the development of gestational diabetes mellitus T2 - Abstract Book 5th RECOOP International Student and 18th RECOOP Bridges in Life Sciences Conferences PB - Recoop HST Association CY - Los Angeles (CA) CY - Budapest SN - 9786156006042 PY - 2023 SP - 70 UR - https://m2.mtmt.hu/api/publication/33775804 ID - 33775804 N1 - p 70 AB - Introduction: The purpose of this study was to investigate the effect of maternal pregestational body mass index (preBMI) on development of gestational diabetes mellitus (GDM). Methods: A retrospective case control study was conducted for pregnancies during the 2-year study period. Women were separated into three groups: normal pregnancy (N=145), preGDM (N=27), GDM (N=41). According to the BMI categories of WHO, pregnants were classified as normal weight (18.5-24.9 kg/m2) or obese (≥30 kg/m2). Diagnostic criteria for preGDM and GDM were based on the guidelines of the Hungarian College of Obstetrics and Gynecology. The Hungarian guideline adopted the National Institute for Health and Care Excellence. (NICE Guideline 3). The oral glucose tolerance test (OGTT) was applied as a screening and diagnostic tool for diabetes. In the test, 75 grams of glucose solution was consumed by the pregnant woman after an 8-hour period of fasting. The glucose level in samples of maternal serum was measured at the start (0 min) and after 120 min. Diagnostic criteria for GDM were: fasting blood glucose level (at 0 min) ≥ 5.6 mmol/l and/or postprandial blood glucose level (at 120 min) ≥ 7.8 mmol/l. If women before subsequent pregnancy had been affected by diabetes mellitus (DM), the OGTT was not performed, but dietary treatment was administered. Patients suffering from preGDM used insulin for treating the disease before pregnancy. High risk pregnancies with respect to GDM were screened with OGTT between the 16th-18th week of gestation, and when the result was below the limit, OGTT was repeated between the 24th-28th week of gestation. Results: The prevalence of pregestational obesity among pregnant women was 25.82% (55/213) [normal: 3.45% (5/145), preGDM: 66.67% (18/27), GDM: 78.05% (32/41)]. Discussion: In women with pregestational obesity increased risk for developing GDM can be detected, that leads to a significantly higher risk for adverse perinatal outcome in Hungary. Conclusion: Pregestational obesity is a risk for developing GDM. LA - English DB - MTMT ER - TY - CHAP AU - Kolcsár, Bálint AU - Altorjay, Ábel Tamás AU - Nyári, Tibor András AU - Németh, Gábor László AU - Surányi, Andrea ED - Edward, Prunchunas ED - Sandor, G. Vari ED - Simona, Lauerova ED - Csaba, Vladar TI - Effect of maternal pregestational BMI on perinatal outcomes in pregestational and gestational diabetes T2 - Abstract Book 5th RECOOP International Student and 18th RECOOP Bridges in Life Sciences Conferences PB - Recoop HST Association CY - Los Angeles (CA) CY - Budapest SN - 9786156006042 PY - 2023 SP - 69 UR - https://m2.mtmt.hu/api/publication/33775774 ID - 33775774 N1 - p 69 AB - Introduction: The purpose of this study was to investigate the effect of maternal pregestational body mass index (preBMI) on perinatal outcomes in pregestational diabetes mellitus (preGDM) and in gestational diabetes mellitus GDM. Methods: A retrospective case control study was conducted for pregnancies during the 2-year study period. Women were separated into three groups: normal pregnancy (N=145), preGDM (N=27), GDM (N=41). According to the BMI categories of WHO, pregnants were classified as normal weight (18.5-24.9 kg/m2) or obese (≥30 kg/m2). Diagnostic criteria for preGDM and GDM were based on the guidelines of the Hungarian College of Obstetrics and Gynecology. The Hungarian guideline adopted the National Institute for Health and Care Excellence. (NICE Guideline 3). We examined the following pregnancy and neonatal outcomes: Cesarean section, perinatal complications (breathing problem, hypoglycemia, polycythemia), birth weight, birth length, 1-minute, 5-minute and 10-minute Apgar scores, admission to the neonatal intensive care unit (NICU) and umbilical cord arterial pH. Results: Transmission to the neonatal intensive unit was 22.53% (48/213) with an increased rate in diabetic groups [GDM: 41.46% (17/41), preGDM: 14.81% (4/27)] compared to healthy controls [13.79% (20/145)]. The average rate of perinatal complications was the highest in GDM group (16.98%) compared to control (14.19%) and preGDM (5.56%) groups. The risk of perinatal complications was elevated in diabetic groups (GDM; preGDM) compared to the control group (aOR: 4.52,95% CI:2.20-9.27). It was demonstrated that obese women are more likely to have perinatal complications (preGDM: aOR 1.17,95% CI:0.72-2.82; GDM: aOR77.77 95% CI:27.42-220.51). Discussion: In women affected by GDM we can detect even higher risk for adverse perinatal outcome in Hungary. Conclusion: Pregestational obesity is a risk for perinatal complications. LA - English DB - MTMT ER - TY - JOUR AU - Paszt, Attila AU - Simonka, Zsolt AU - Budai, Krisztina AU - Horváth, Zoltán AU - Erdos, Marton AU - Vas, Márton Árpád AU - Ottlakán, Aurél AU - Nyári, Tibor András AU - Szepes, Zoltán AU - Uhercsák, Gabriella AU - Maráz, Anikó AU - Torday, László AU - Tiszlavicz, László AU - Oláh, Judit Magdolna AU - Lázár, György ifj TI - Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy JF - FRONTIERS IN SURGERY J2 - FRONT SURG VL - 10 PY - 2023 PG - 13 SN - 2296-875X DO - 10.3389/fsurg.2023.1148984 UR - https://m2.mtmt.hu/api/publication/33729458 ID - 33729458 N1 - Eredeti közlés, másodközlés rekordja: 34426094 LA - English DB - MTMT ER - TY - GEN AU - Kolcsár, Bálint AU - Altorjay, Ábel Tamás AU - Nyári, Tibor András AU - Németh, Gábor László AU - Surányi, Andrea TI - Az anyai pregesztációs testtömegindex hatása a perinatális kimenetelre pregesztációs és terhességi diabetes mellitusban PY - 2023 UR - https://m2.mtmt.hu/api/publication/33685481 ID - 33685481 N1 - Előadás száma:36 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Cserni, Bálint Gábor AU - Kilmartin, Darren AU - O’Loughlin, Mark AU - Andreu, Xavier AU - Bagó-Horváth, Zsuzsanna AU - Bianchi, Simonetta AU - Chmielik, Ewa AU - Figueiredo, Paulo AU - Floris, Giuseppe AU - Foschini, Maria Pia AU - Kovács, Anikó AU - Heikkilä, Päivi AU - Kulka, Janina AU - Laenkholm, Anne-Vibeke AU - Liepniece-Karele, Inta AU - Marchiò, Caterina AU - Provenzano, Elena AU - Regitnig, Peter AU - Reiner, Angelika AU - Ryška, Aleš AU - Sapino, Anna AU - Stovgaard, Elisabeth Specht AU - Quinn, Cecily AU - Zolota, Vasiliki AU - Webber, Mark AU - Glynn, Sharon A. AU - Bori, Rita AU - Csörgő, Erika AU - Oláh, Orsolya AU - Pancsa, Tamás AU - Sejben, Anita AU - Sejben, István AU - Vörös, András AU - Zombori, Tamás AU - Nyári, Tibor András AU - Callagy, Grace AU - Cserni, Gábor TI - ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations JF - CANCERS J2 - CANCERS VL - 15 PY - 2023 IS - 4 PG - 11 SN - 2072-6694 DO - 10.3390/cancers15041199 UR - https://m2.mtmt.hu/api/publication/33649494 ID - 33649494 N1 - TNG Technology Consulting GmbH, Király u. 26, Budapest, 1061, Hungary Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, H91 TK33, Ireland Pathology Department, Atryshealth Co., Ltd, Barcelona, 08039, Spain Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria Division of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, 50134, Italy Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, 44-102, Poland Laboratório de Anatomia Patológica, IPO Coimbra, Coimbra, 3000-075, Portugal Laboratory of Translational Cell & Tissue Research, KU Leuven, Department of Imaging and Pathology, Department of Pathology, University Hospitals Leuven, University of Leuven, Oude Market 13, Leuven, 3000, Belgium Unit of Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bellaria Hospital, Bologna, 40139, Italy Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, 41345, Sweden Department of Pathology, Helsinki University Central Hospital, Helsinki, 00029, Finland Department of Pathology, Forensic and Insurance Medicine, Semmelweis University Budapest, Üllői út 93, Budapest, 1091, Hungary Department of Surgical Pathology, Zealand University Hospital, Roskilde, 4000, Denmark Department of Pathology, Riga Stradins University, Riga East Clinical University Hospital, Riga, LV-1038, Latvia Unit of Pathology, Candiolo Cancer Institute FPO-IRCCS, Candiolo, 10060, Italy Department of Medical Sciences, University of Turin, Turin, 10126, Italy Department of Histopathology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, CB2 0QQ, United Kingdom National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, CB2 0QQ, United Kingdom Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, 8010, Austria Department of Pathology, Klinikum Donaustadt, Vienna, 1090, Austria The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, 50003, Czech Republic Pathology Department, Herlev University Hospital, Herlev, DK-2730, Denmark Department of Histopathology, Irish National Breast Screening Programme, BreastCheck, St. Vincent’s University Hospital and School of Medicine, University College Dublin, Dublin, D04 T6F4, Ireland School of Medicine, University College Dublin, Dublin, D04 V1W8, Ireland Department of Pathology, School of Medicine, University of Patras, Rion, 26504, Greece Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, 6000, Hungary Department of Pathology, University of Szeged, Szeged, 6720, Hungary Department of Medical Physics and Informatics, University of Szeged, Szeged, 6720, Hungary Cited By :1 Export Date: 25 September 2023 Correspondence Address: Cserni, G.; Department of Pathology, Hungary; email: csernig@kmk.hu AB - Tumour-infiltrating lymphocytes (TILs) reflect antitumour immunity. Their evaluation of histopathology specimens is influenced by several factors and is subject to issues of reproducibility. ONEST (Observers Needed to Evaluate Subjective Tests) helps in determining the number of observers that would be sufficient for the reliable estimation of inter-observer agreement of TIL categorisation. This has not been explored previously in relation to TILs. ONEST analyses, using an open-source software developed by the first author, were performed on TIL quantification in breast cancers taken from two previous studies. These were one reproducibility study involving 49 breast cancers, 23 in the first circulation and 14 pathologists in the second circulation, and one study involving 100 cases and 9 pathologists. In addition to the estimates of the number of observers required, other factors influencing the results of ONEST were examined. The analyses reveal that between six and nine observers (range 2–11) are most commonly needed to give a robust estimate of reproducibility. In addition, the number and experience of observers, the distribution of values around or away from the extremes, and outliers in the classification also influence the results. Due to the simplicity and the potentially relevant information it may give, we propose ONEST to be a part of new reproducibility analyses. LA - English DB - MTMT ER - TY - CHAP AU - Németh, Kristóf AU - Nyári, Tibor András ED - Bari, Ferenc ED - Rárosi, Ferenc ED - Szűcs, Mónika TI - Gyerekkori daganatos betegségek morbiditásának és mortalitásának vizsgálata Magyarországon 1999-2021 között T2 - Az egészségügyi informatika COVID előtt és COVID után - A XXXV. Neumann Kollokvium konferencia kiadványa PB - Neumann János Számítógép-tudományi Társaság CY - Szeged SN - 9786155036224 PY - 2022 SP - 173 EP - 176 PG - 4 UR - https://m2.mtmt.hu/api/publication/33575313 ID - 33575313 LA - Hungarian DB - MTMT ER -